444s268
NM_001164750.1 NM_001164751.1 NM_001164752.1 NM_001164753.1 NM_001164754.1 NM_001164755.1 NM_001164756.1 NM_004318.3 NM_020164.4 NM_032466.3 NM_032467.3 NM_032468.4 XM_005251235.2 XM_005251236.2 XM_005251238.2 XM_005251239.2 XM_005251240.1 XM_005251242.2 XM_005251243.2 XM_005251244.1 XM_005251246.2 XM_005251247.2 XM_005251248.1 XM_005251250.2 XM_017013419.1 XM_017013420.1 XM_017013421.1 XM_017013422.1 XM_017013423.1 XM_017013424.1 XM_017013425.1 XM_017013426.1 XM_017013427.1 XM_017013428.1 XM_017013429.1 XM_017013430.1 XM_017013431.1 XM_017013432.1 XM_017013433.1 XM_017013434.1 XM_017013435.1 XM_017013436.1 XM_017013437.1 XM_017013438.1 XM_017013439.1 XM_017013440.1 XM_017013441.1 XM_017013442.1 XM_017013443.1 XM_017013444.1 XM_017013445.1 XM_017013446.1 XM_017013447.1
7%(+/-4% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00188872_m1]
HeLa cells were reverse transfected with 5 nM gene-specific Silencer® Select siRNA or 5 nM Silencer® Select Negative Control #2 siRNA, using siPORT™ NeoFX™ Transfection Agent. 48 hours post-transfection, RNA was isolated, and then two-step, quantitative RT-PCR was performed using an appropriate TaqMan® Gene Expression Assay. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.